Wanbury (WANBURY)₹200.71−0.14%Pharmaceuticals
In the Mar 2026 quarter (standalone), Wanbury reported sales of ₹165 Cr, down 4.1% from Mar 2025, and net profit of ₹21.93 Cr, up 10.0% year on year. For the year to Mar 2026, sales were ₹648 Cr and net profit ₹65.78 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 146 | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 | 160 | 162 | 165 |
| Expenses | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 | 134 | 136 | 135 |
| Operating Profit | 13.02 | 17.03 | 21.03 | 18.02 | 11.02 | 20.03 | 14.02 | 30.07 | 24.04 | 26.06 | 27.06 | 30.05 |
| OPM % | 8.9% | 11.9% | 14.9% | 13.0% | 7.9% | 11.9% | 9.9% | 17.0% | 14.9% | 15.9% | 15.9% | 17.9% |
| Other Income | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 1.99 | 0.00 | 0.00 | 0.00 | −2.99 |
| Interest | 6.02 | 8.02 | 8.03 | 7.01 | 8.03 | 10.02 | 10.03 | 9.03 | 8.03 | 7.02 | 7.02 | 8.03 |
| Depreciation | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.98 | 3.98 | 3.99 | 2.99 |
| Profit before tax | 4.99 | 6.99 | 9.98 | 7.99 | 0.99 | 7.99 | 0.99 | 18.97 | 13.97 | 14.98 | 15.98 | 14.97 |
| Tax % | 6.0% | −2.0% | 0.0% | 3.0% | 0.0% | 2.0% | 5.0% | −6.0% | 1.0% | 0.0% | 1.0% | −43.1% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −3.46 |
| Net Profit | 4.99 | 6.99 | 9.96 | 7.98 | 0.99 | 7.98 | 0.99 | 19.93 | 12.97 | 14.95 | 15.97 | 21.93 |
| EPS (Rs) | 1.44 | 2.26 | 3.15 | 2.48 | 0.33 | 2.46 | 0.38 | 6.19 | 4.11 | 4.36 | 4.53 | 6.22 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 419 | 431 | 369 | 390 | 366 | 391 | 510 | 499 | 576 | 598 | 648 | 648 |
| Expenses | 387 | 414 | 438 | 375 | 344 | 374 | 474 | 475 | 506 | 523 | 544 | 544 |
| Operating Profit | 34.04 | 19.03 | −68.08 | 16.03 | 23.06 | 18.02 | 36.04 | 23.05 | 72.09 | 77.17 | 107 | 107 |
| OPM % | 8.0% | 4.3% | −18.1% | 4.1% | 6.0% | 4.7% | 7.0% | 4.7% | 12.0% | 13.0% | 15.9% | 16.5% |
| Other Income | 0.00 | 89.61 | 75.69 | 8.97 | 83.65 | 1.99 | 76.74 | 0.00 | 0.99 | 2.99 | −2.99 | −2.99 |
| Interest | 32.09 | 36.10 | 31.08 | 40.13 | 33.10 | 23.07 | 21.05 | 21.05 | 29.06 | 37.13 | 30.10 | 30.10 |
| Depreciation | 8.97 | 9.96 | 9.97 | 9.96 | 9.97 | 9.96 | 10.96 | 11.95 | 12.95 | 12.96 | 13.95 | 14.94 |
| Profit before tax | −6.98 | 61.84 | −31.93 | −24.94 | 64.85 | −11.97 | 80.87 | −9.98 | 30.96 | 29.95 | 59.87 | 59.90 |
| Tax % | 0.0% | 1.0% | −1.0% | −1.0% | 0.0% | 2.0% | 0.0% | 1.0% | 1.0% | −3.0% | −11.1% | — |
| Exceptional items | −1.01 | 0.00 | 0.00 | 0.00 | 83.13 | 1.01 | 76.10 | 0.00 | 0.00 | 1.01 | −4.01 | −3.46 |
| Net Profit | −6.98 | 61.85 | −31.92 | −24.92 | 63.78 | −12.97 | 80.77 | −9.97 | 29.93 | 30.90 | 65.78 | 65.82 |
| EPS (Rs) | −3.53 | 26.74 | −13.52 | −10.50 | 25.82 | −5.05 | 24.99 | −3.19 | 9.30 | 9.34 | 18.97 | 19.22 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.09 | 20.09 | 23.08 | 24.08 | 24.08 | 25.09 | 25.08 | 33.14 | 33.15 | 33.11 | 33.13 | 35.14 |
| Reserves | −188 | −183 | −151 | −183 | −207 | −143 | −156 | −29.93 | −39.95 | −4.99 | 25.95 | 110 |
| Borrowings | 382 | 374 | 274 | 225 | 233 | 164 | 166 | 74.17 | 68.14 | 116 | 179 | 225 |
| Other Liabilities | 181 | 175 | 264 | 206 | 235 | 231 | 253 | 275 | 241 | 199 | 176 | 149 |
| Total Liabilities | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 | 519 |
| Fixed Assets | 164 | 180 | 187 | 178 | 172 | 164 | 168 | 167 | 168 | 167 | 201 | 230 |
| CWIP | 19.05 | 14.05 | 10.03 | 10.03 | 9.03 | 14.04 | 11.04 | 2.01 | 2.01 | 3.01 | 5.01 | 25.07 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 212 | 192 | 215 | 82.92 | 103 | 98.86 | 109 | 182 | 133 | 173 | 208 | 263 |
| Inventories | 34.08 | 35.07 | 34.09 | 13.03 | 19.04 | 12.02 | 25.04 | 50.09 | 22.05 | 36.08 | 38.11 | 51.09 |
| Trade receivables | 99.13 | 75.09 | 85.15 | 29.05 | 44.04 | 51.09 | 34.02 | 63.13 | 69.09 | 89.10 | 114 | 143 |
| Cash & equivalents | 11.95 | 6.98 | 8.97 | 5.98 | 4.98 | 16.93 | 11.96 | 24.91 | 3.99 | 5.98 | 12.94 | 7.97 |
| Total Assets | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 | 519 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 40.04 | 43.06 | 43.03 | 32.02 | 30.03 | 44.09 | 17.02 | 41.04 | 20.03 | 5.01 | 26.05 | 32.06 |
| Cash from investing activity | −4.99 | −19.98 | −12.99 | −0.99 | −2.99 | 63.94 | 7.99 | 0.99 | −8.99 | −16.97 | −50.93 | −55.99 |
| Cash from financing activity | −29.98 | −27.98 | −26.96 | −32.93 | −26.95 | −108 | −16.99 | −28.96 | −31.95 | 13.98 | 25.96 | 21.97 |
| Net cash flow | 5.01 | −5.02 | 3.01 | −2.01 | 0.00 | 0.00 | 7.02 | 13.03 | −21.05 | 2.01 | 1.01 | −2.01 |
| Capex | 4.99 | 20.99 | 14.99 | 3.01 | 4.99 | 7.99 | 3.99 | 9.99 | 13.01 | 16.99 | 48.99 | 59.94 |
| Free cash flow | 35.12 | 22.10 | 29.11 | 30.10 | 25.10 | 36.11 | 12.04 | 42.14 | 7.03 | −9.04 | −23.08 | −28.09 |
| CFO / OP % | 186.9% | 128.9% | 233.9% | −49.1% | 187.9% | 188.0% | 96.9% | 113.0% | 85.9% | 6.9% | 34.9% | 29.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 50 | 56 | 70 | 80 |
| Inventory days | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 | 67 |
| Days payable | 300 | 171 | 259 | 173 | 208 | 252 | 220 | 218 | 178 | 196 | 172 | 142 |
| Cash conversion cycle | −54 | −37 | −124 | −117 | −131 | −176 | −147 | −112 | −101 | −96 | −55 | 6 |
| Working capital days | −139 | −123 | −164 | −251 | −230 | −211 | −227 | −134 | −129 | −37 | 4 | 17 |
| ROCE % | — | 12.1% | 55.0% | −1.0% | 26.0% | 31.1% | 23.1% | 46.1% | 17.1% | 58.1% | 34.1% | 31.1% |
For the Mar 2026 quarter, Wanbury reported sales of ₹165 Cr, down 4.1% year on year and net profit of ₹21.93 Cr, up 10.0% year on year. The operating margin was 17.9%.
Wanbury's sales for the year to Mar 2026 were ₹648 Cr; over the last twelve months they were ₹648 Cr.
Net profit for the year to Mar 2026 was ₹65.78 Cr, and ₹65.82 Cr over the last twelve months. Earnings per share over the same trailing period were ₹19.22.
Wanbury reported borrowings of ₹225 Cr at Mar 2026, against cash and equivalents of ₹7.97 Cr.
Cash from operations was ₹32.06 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹28.09 Cr.